~~<i id='12C51D5848'><strike id='12C51D5848'><tt id='12C51D5848'><pre id='12C51D5848'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

leisure time

author：explore 2025-09-29 01:35:12 - browse：97588

HHS 2020 — PhRMA is suing the Biden administration over its new Medicare drug price negotiation program. Graeme Sloan/Sipa USA

WASHINGTON — After losing the drug pricing fight on Capitol Hill, PhRMA is taking its battle to the courts.

The pharmaceutical industry’s biggest lobbying group on Wednesday filed a long-expected lawsuit challenging Democrats’ drug pricing law that allowed Medicare to start negotiating prices for certain medicines.

PhRMA joins a growing club of companies and trades challenging the law. Merck, Bristol Myers Squibb, and the Chamber of Commerce have already filed similar suits in different courts.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Primary care physicians play key roles in Alzheimer's management

entertainment

leisure time

hotspot

leisure time

AdobeTodayistheinauguralpublishingdayforAdam’sBiotechScorecard—asubscriber-onlynewsletterofferingsen

WSS

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Patient advocates debate FDA's accelerated approval process

A look at other Americans who have crossed into North Korea over the years

Robert Kennedy Jr.'s presidential campaign attracts GOP

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

focus

leisure time

entertainment

Cancer drug shortages should be causing more outrage

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

Hollywood unions extend contract negotiations for actors

Readout LOUD podcast: mifepristone case, GLP

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Readout Newsletter: Merck, Vertex, and Viking updates

Heart attack and stroke risk calculators need revising

FDA's naming rule on biosimilars has undermined competition

What does generative AI mean for health care? We asked experts

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

leisure time

Twill hunts for pharma partner to market its depression app

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

States should stop sabotaging methadone treatment reform

Study: Hearing aids may slow cognitive decline in those at risk

There's no autism epidemic. It's an autism diagnosis epidemic

Biden administration sends mixed signals on US soldier who crossed into North Korea

hotspot

leisure time

leisure time

leisure time